Details of the Drug

General Information of Drug (ID: DMFRQJ3)

Drug Name
2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one
Synonyms
864224-08-8; 2-(PHENYLETHYNYL)-7,8-DIHYDROQUINOLIN-5(6H)-ONE; CHEMBL252956; 2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one; 5(6H)-Quinolinone, 7,8-dihydro-2-(phenylethynyl)-; SCHEMBL4325876; 2-(2-phenylethynyl)-7,8-dihydro-6H-quinolin-5-one; CTK3C7284; DTXSID10464098; XOUDFZJCSDKXLG-UHFFFAOYSA-N; ZINC28967975; BDBM50231741; AKOS025146642; SC-68865; AK164588; AS-41243; 2-(Phenylethynyl)-7,8-dihydroquinolin-5(6H)-one, 98%
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 247.29
Topological Polar Surface Area (xlogp) 3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C17H13NO
IUPAC Name
2-(2-phenylethynyl)-7,8-dihydro-6H-quinolin-5-one
Canonical SMILES
C1CC2=C(C=CC(=N2)C#CC3=CC=CC=C3)C(=O)C1
InChI
InChI=1S/C17H13NO/c19-17-8-4-7-16-15(17)12-11-14(18-16)10-9-13-5-2-1-3-6-13/h1-3,5-6,11-12H,4,7-8H2
InChIKey
XOUDFZJCSDKXLG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
11379626
CAS Number
864224-08-8
TTD ID
D0QE3C

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Metabotropic glutamate receptor 5 (mGluR5) TTHS256 GRM5_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Metabotropic glutamate receptor 5 (mGluR5) DTT GRM5 9.81E-07 -0.26 -0.54
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
2 Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
3 Pipeline of Addex Pharma. Addex Pharma. 2009.
4 The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
5 Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
6 A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
7 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
9 Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
10 Clinical pipeline report, company report or official report of Roche.
11 mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.